1.Expression and clinical significance of vascular endothelial growth factor in human non-small cell lung cancer.
Bin LI ; Xuewen CAO ; Jianhua ZHANG ; Junwei JIANG ; Yongzhu YANG ; Yunjiu GOU
Chinese Journal of Lung Cancer 2004;7(2):142-145
BACKGROUNDTo investigate the expression of vascular endothelial growth factor (VEGF) and its relation to clinical characteristics and prognosis of non-small cell lung cancer (NSCLC), and to study the possible mechanism of VEGF.
METHODSThe expression of VEGF and intratumoral microvascular density (MVD) were determined in 96 NSCLC tissues by SP immunohistochemical method.
RESULTSVEGF was mainly stained in the cytoplasm of tumor cells. The positive rate of VEGF expression was 64.6% in 96 patients. The positive rate of VEGF expression was related to stages (P=0.041), but not to other clinical characteristics of NSCLC (P > 0.05). The expression of VEGF in high MVD group (80.4%) was significantly higher than that in low MVD group (46.7%) (P=0.001). The patients with positive VEGF expression had a significantly shorter survival duration than those with negative VEGF expression (P < 0.01). By Cox proportional hazard model analysis, the expression of VEGF and clinical stage were considered the independent predictors for the prognosis of NSCLC.
CONCLUSIONSThe results suggest that VEGF plays an important role in the angiogenesis of NSCLC, and that detection of VEGF expression may be helpful to predict prognosis of NSCLC.
2.H9 embryonic stem cell-derived extracellular vesicles promote endome-trial repair
Zhiqi CHEN ; Jing MA ; Yongzhu JIANG ; Guanrong MA ; Bangya YANG ; Lanxi WANG ; Liaoqiong FANG ; Zhibiao WANG
Chinese Journal of Pathophysiology 2024;40(8):1497-1504
AIM:To investigate the reparative effect of extracellular vesicles(EVs)derived from H9 human embryonic stem cells(H9-hESCs)on endometrial injury.METHODS:EVs were isolated from the culture supernatant of H9-hESCs and characterized.A mouse model of endometrial injury was established,with bilateral uterine divisions into an EVs experimental group and a PBS control group.EVs and PBS were injected respectively.Histological changes in the endometrium were assessed using HE staining,and proliferating cell nuclear antigen(PCNA)expression was analyzed via immunohistochemistry.The impact of EVs on the proliferation of human endometrial stromal cells(hEndoSCs)was eva-luated using EdU staining and Western blot.RESULTS:H9-hESCs-EVs exhibited a membrane-structured nanobody with a particle size of(144.7±2.1)nm and expressed characteristic proteins CD63 and TSG101.Compared to the PBS control group,the EVs group showed increased endometrial tissue morphology,thickness,and gland numbers.The average opti-cal density of PCNA expression significantly increased in the EVs group compared to the PBS group(P<0.05).Results from EdU staining and Western blot demonstrated that H9-hESCs-EVs promoted hEndoSC proliferation,with a positive correlation observed between H9-hESCs-EVs and EVs protein concentration(P<0.05).CONCLUSION:H9-hESCs-EVs enhance the repair of endometrial injury by stimulating the proliferation of endometrial stromal cells.
3.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.